Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19624259 | 0.73 | NFKB1 (0.51) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21099276 | 0.69 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL31491328 | 0.68 | KIF11 (0.41) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL375687 | 0.68 | PDE4B (0.44) | RAB9ASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL31469077 | 0.68 | SYK (0.41) | RAB9ASMN1; SMN2MAPTMEN1POLB | |
| SCHEMBL2062060 | 0.68 | JAK2 (0.40) | MEN1KMT2AHTTPLK4PAK4 | |
| SCHEMBL17304181 | 0.68 | PLK4 (0.36) | MEN1KMT2AHTTPLK4PAK4 | |
| SCHEMBL4511831 | 0.68 | PAK1 (0.40) | HTTPAK4 | |
| SCHEMBL2917889 | 0.67 | KMT2A (0.36) | SMN1; SMN2KMT2A | |
| SCHEMBL13211477 | 0.67 | HPGD (0.46) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | NPC1 592/4885RAB9A 2239/4885SMN1; SMN2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.